Therefore, a comprehensive analysis of each histone deacetylase (HDAC) to determine its individual functions in inflammation and MS is essential to evaluate specific HDAC targets for optimal use of HDACi as potential MS treatments. This evidence concerns the gene HDAC9 and myeloid sarcoma.